The Academy is proud to host BioMedica 2020 – A Virtual Festival of Medical Science.

Below is the programme and timing of the various sessions.

To view the content of each session, simply use the + sign near to the session timing to access a synopsis of the presentations to be held, abstracts, learning outcomes and speaker details.

Please register for each of the individual sessions you wish to attend.

Festival Programme

30th November

Click here to register

Welcome Address from Bernadette Jackson, President of the Academy of Clinical Science and Laboratory Medicine

Click to register

Chair: Dr. Claire Wynne, Lecturer in Haematology, Undergraduate CPD Coordinator, TU Dublin.

13:00-13:30 E pluribum Unum: the many causes of Thrombotic Microangiopathy

Dr. Maeve Crowley, Consultant Haematologist, Comprehensive Coagulation Centre, Cork University Hospital.

Maeve graduated from University College Cork and did her haematology higher specialist training in Ireland. She was awarded an MD for her work on the coagulopathy associated with plasma cell disorders. On completion of her training, she worked as a consultant haematologist in the Haemostasis and Thrombosis centre in Guy’s and St Thomas’ hospital in London. While there, she was the lead for thrombotic microangiopathy and developed interests in antiphospholipid syndrome and obstetric haematology. She is currently a consultant haematologist in the comprehensive coagulation centre in Cork University Hospital.

Thrombotic microangiopathies are a group of disorders characterized by microangiopathic haemolytic anemia, thrombocytopenia and organ damage due to microvascular thrombosis. Though rare, thrombotic microangiopathies are often life-threatening and can require urgent management. Presenting symptoms are often nonspecific, but basic laboratory tests reveal a specific constellation of thrombocytopenia and anaemia with red blood cell fragmentation on the blood film and evidence of haemolysis.

13:30-14:00 Non-thrombotic effects of platelets.

Associate Professor Niamh Moran and Steven Cullen , Molecular & Cellular Therapeutics, School of Postgraduate Studies, Royal College of Surgeons Ireland.

Proffessor Niamh Moran is a biochemical pharmacologist who has devoted much of her research career to the understanding of the molecular events underlying platelet activation. She has developed a number of high throughput assays for assessing platelet function that can identify platelet activation in clinical samples. The work of her laboratory has demonstrated independent regulation of platelet activation events in homeostasis and haemostasis, in health and disease.

Abstract: Niamh Moran, Steven Cullen, Brendan McDonnell, Carmen Regan

Platelets play a key role in thrombosis and haemostasis. However recent evidence clearly demonstrates that the functional role of platelets extends to many other processes in the body.

In haemostasis, platelets survey the blood vessels for evidence of damage. Upon detection of endothelial injury, platelets undergo a rapid regulated activation which results in dramatic shape change, adhesion to the exposed sub-endothelial matrix, secretion of important effectors from their dense granules and alpha-granules. The contents of the platelet granules are key to understanding the role of platelets in downstream events. We recently demonstrated that tumour cells directly and specifically induced platelet secretion. Moreover, tumour cell-induced platelet secretion results in the selective release of pro angiogenetic cytokines and mediators, suggestive of a pro-metastatic role for platelets in cancer growth and development.

In parallel, while it is well-established that profound alterations to the blood’s haemostatic balance favouring a pro-coagulant status is observed in normal human pregnancy, little is understood about the role of platelets in pregnancy. We present evidence for temporal, trimester-associated, alterations in platelet function in healthy pregnancy. This nuanced modulation of platelet function associated with progression of pregnancy is suggestive of a functional role for platelet activation during normal gestation. Alterations in platelet activity occur during normal pregnancy have been linked to placental disorders such as pre-eclampsia and fetal growth restriction (FGR). Cigarette smoking increases risk of arterial thrombosis through platelet activation and in pregnancy is a leading cause of FGR. We also demonstrate a differential change in global platelet responsiveness in pregnant women who smoke.

In summary, we will present evidence for the additional role of platelets outside thrombosis and haemostasis, in modulating physiological events as diverse as cancer metastasis and placental development.

A replay of today’s webinars

1st December

Click here to register

Chair: Fergus Guilfoyle, Chief Medical Scientist, Coombe Womens & Infants University Hospital, Dublin

11:00-11.30 An Audit of the Appropriate Use of O Rh D Negative Red Blood Cells in a Large Teaching Hospital

Claire Buckley, Medical Scientist, Blood Transfusion, St. James’s Hospital, Dublin

Claire is a Medical Scientist working in The Blood Transfusion Laboratory at St James’s Hospital (SJH). She completed her clinical laboratory placement in SJH and carried out her 4th year research project in the Blood Transfusion Laboratory there. Claire graduated from TU-Dublin in 2019. She majored/minored in Blood Transfusion/Microbiology.

This project was designed to investigate if O RhD negative red cell units are being transfused appropriately by auditing their usage in 2018. The main aims were; to examine O RhD negative usage in terms of patient cohort, measure existing blood stock management performance with regards to the optimisation of O RhD negative red cell usage and aid in future forecasting by SJH and the IBTS. These goals were achieved via the development of a purpose built excel datasheet. This datasheet was designed to gather data on all O RhD negative units received by SJH from the IBTS in 2018. The data collected was then statistically analysed.
Some of the results yielded from this project include; Overall RhD Negative usage, O Negative wastage, O Negative usage by Haemoglobinopathy patients and O Negative usage by BMT/PBSCT patients’.


Stephen Cousins, Donor Services Manager, IBTS


12:00-12:30 The National Blood Stock Shortage Plan

Dr. Joan Power, MB FRCPI, FFPath

Clinical Lead Advisor Transfusion Services.  Consultant Haematologist, Irish Blood Transfusion Service.  Secretary to National Transfusion Advisory Group.

Medical graduate UCC.  Initial appointment Consultant Haematologist/ Munster Regional Director, BTSB.  Currently Consultant Haematologist IBTS, Medical Director Therapeutic Apheresis Service.   Senior Clinical Lecturer UCC.  Board member Faculty of Pathology, RCPI.  Former Medical Director Munster Musculoskeletal Tissue Bank and Past President British Association for Tissue Banking.  Following her identification of the Hepatitis C contamination of BTSB anti-D Immunoglobulin in 1994, National Co-Ordinator to 1997.  Awarded UCC Medical Faculty Gold Medal for outstanding contribution to Medicine in Society (2002).  Committed to Quality and Clinical Governance frameworks in Health Service delivery, led Munster Centre to ISO and CPA accreditation and contributed at European level to Directives Development.

Click here to register

Chair: Dr. Claire Wynne, Lecturer in Haematology, Undergraduate CPD Coordinator, TU Dublin

13:00-13:30 Mutation Status in Myeloid Malignancies informs clinical insight 

Dr Karl Haslam, Senior Scientist, GMI Genomics Centre at Genomics Medicine Ireland

The last decade has seen significant development in understanding the genetic basis of myeloproliferative neoplasms (MPN), with the underlying somatic mutational landscape revealed by genome and targeted exome sequencing. To develop insight into the utility and clinical application of these disease markers, a series of original investigations was conducted. Initially three recently identified disease-specific molecular markers (mutations in JAK2, CALR and CSF3R) were utilised to measure the burden of disease post-allogeneic transplantation using methods based on quantitative PCR, capillary electrophoresis and Sanger sequencing. All three mutation markers were shown to be stable and robust for monitoring purposes throughout the disease course, inversely correlating with percentage donor chimerism. Increased sensitivity using qPCR in one study highlighted the potential of these disease specific markers to detect molecular and haematological relapse in patients several weeks before clinical manifestation and proved an advantageous adjunct in the clinical assessment of transplantation efficacy. In a second series of studies, the incidence and significance of recurrent MPN mutations in specific clinical scenarios and MPN disease cohorts was investigated. A baseline for the incidence of JAK2, CALR and MPL mutations in Irish patients referred for suspected MPN was established and shown to be comparable with that of other Western European cohorts. To extend this finding, the incidence and significance of these mutations was investigated in specific clinically relevant disease cohorts, revealing a distinct molecular pathogenesis in paediatric patients with essential thrombocythaemia (ET) when compared to adults, a low incidence of CALR mutations in splanchnic vein thrombosis patients that correlated with the aetiology of the disease and the presence of CALR driver mutations in familial MPN cases. Additionally, the presence of a JAK2 V617F mutation in utero in ET was established for the first time and the dynamic nature of MPN disease clones over the course of disease was revealed, thus informing insight into the clonal evolution and molecular heterogeneity of MPN patients. In the third series of studies novel next generation sequencing (NGS) technology was applied to investigate somatic mutations in acute myeloid leukaemia (AML) related patient cohorts. A proprietary NGS panel for recurrently mutated genes possessing diagnostic and prognostic significance in AML was evaluated on the Ion Torrent (ThermoFisher) NGS platform across three molecular diagnostic centres in Ireland, Northern Ireland and Scotland. This verified the technique to be robust and reproducible for mutation detection in AML patients. The technology was subsequently deployed to profile mutation status in a clinically high-risk AML patient cohort undergoing transplantation therapy and in a familial AML disease setting to clarify the genotype, reveal the diverse clonal architecture of patients and identify additional driver mutations relevant for existing and emerging therapeutic interventions. Taken together, these studies inform clinical understanding and decision making in MPN and AML related settings, provide novel insight into underlying mutational status and clonal behaviour in myeloid malignancies and have the potential to translate into optimised and improved treatment for these patient cohorts.


13:30-14:00 Evaluation of Rotational Thromboelastometry (ROTEM®) in an Irish obstetric population 

Deirdre Duggan, Senior Medical Scientist, Haematology, National Maternity Hospital, Dublin

Deirdre Graduated with a BSc Biomedical Science in 2014 from joint CIT/UCC programme. Following a brief stint in Microbiology Deirdre started in the Haematology Laboratory of the National Maternity Hospital in 2017 where her interest for Obstetric Haematology developed. Deirdre graduated with an MSc in Clinical Laboratory Science from TU Dublin in 2019. She is currently working as the Quality Officer for the Deptartment of Pathology & Laboratory Medicine at the National Maternity Hospital.

Assessment of maternal haemostatic capacity is a critical component of post-partum haemorrhage management. Recently the utility of standard laboratory testing of haemostasis during obstetric haemorrhage has been questioned. ROTEM® analysis provides a rapid, near-patient assessment of coagulation status which may offer a solution to the limitations of current methods.

14:00-14:30 The Determination of Paroxysmal Nocturnal Haemoglobinuria clone size in CD71 Positive Red Blood Cells. 

Ellen O’Connor, Medical Scientist, Haematology & Blood Transfusion, Rotunda Hospital, Dublin.

Ellen graduated from TU Dublin in 2019. She completed her final year project in the flow cytometry laboratory in the Haematology laboratory in St. James’s Hospital. She now works as a medical scientist in the Haematology/ Blood Transfusion laboratory in the Rotunda Hospital.

The size of the RBC clone in PNH is often underestimated due to transfusion or haemolyisis. The superiority of reticulocyte analyses over RBC analyses has been suggested because of its transfusion and haemolysis independency.
The aim of this investigation was to determine the PNH reticulocyte clone size and compare this to the corresponding neutrophil and monocyte clone size. Flow cytometric analysis using the BD FACSCantoTM II flow cytometer was performed on 22 patients. The determination of PNH reticulocyte clone size was made by analysing CD59 expression on CD71 positive red blood cells by flow cytometry

Click here to register

Chair: Hayley Foy-Stones, Medical Scientist, Haematology Department, St James’s Hospital & Chair of the Engagement and Advancement Advisory Body with the Academy of Clinical Science and Laboratory Medicine.

15:00-15:20 Interview Skills for Medical Scientists

John Crumlish, Laboratory Manager, Mater Misericordiae University Hospital (MMUH)

John has worked in MMUH since late 2014. Started as Chief Medical Scientist, Blood Transfusion before taking up laboratory manager post in 2017. Prior to this had worked for IBTS for 23 years in a variety of departments, ending as Chief Medical Scientist in Red Cell ImmunoHaematology Reference Laboratory.


15:20-15:50 Developing the role for Consultant Healthcare Scientists within Pathology – Experiences from the UK.

Dr. Joanne Horne, Consultant Clinical Scientist in Histopathology, University Hospital Southampton NHS. Consultant Healthcare Scientist in Histopathology, HCPC Registered Clinical Scientist, HCPC Registered Biomedical Scientist.

Jo was one of the original participants in the UK national Histopathology Reporting Diploma programme. Since then she has been working as part of the consultant specialty team at Southampton, UK, independently dissecting and reporting gastrointestinal specimens.

Jo is a member of Institute of Biomedical Science (IBMS) Council and deputy chair of the IBMS Membership & Marketing committee. She sits on conjoint boards for the histological dissection and reporting qualifications, and with the National School of Healthcare Science as an examiner for the Scientist Training Programme (STP), and as lead editor for the histopathology STP curriculum review.  Jo is part of a working group reviewing Healthcare Scientist training pathways within histopathology and is passionate about their development and promotion.

Jo’s other interests include compassionate leadership and the use of media to engage, inform and promote the profession, having recently created a website for current and aspiring Healthcare Scientists.  She also provides educational support, advice and mentoring to colleagues and peers.

Advanced practice in histopathology dissection is long established within the UK. In 2012, a pilot scheme was launched to train Healthcare Scientists in histopathology reporting, as there was increasing awareness of the impending workforce crisis within the specialism. As one of the pilot participants I have been involved in training within the UK since the beginning and was in the first cohort to pass the examination and gain certification in gastrointestinal histopathology reporting. This has enabled me to practice independently since 2016 and I was appointed into a Consultant post earlier this year. This talk will firstly look at the training and experiences of those of us who have undertaken the UK histopathology reporting programme. There will then be focus on the wider strategy within the UK relating to advanced and consultant practice for scientists within Pathology. Finally, I will offer some advice on how the same developments might be designed and implemented within Ireland, based on experiences from the UK over the last eight years.


15:50-15:55 Health Service Staff Credit Union – Funding Postgraduate Studies

Pádraig Power, Health Service Staff Credit Union, Marketing Manager

Abstract: Pádriag is providing an overview of the services available to medical scientists from the Health Service Staff Credit Union and the eight most common methods of  funding various types of postgraduate studies.


15:55-16:00 MLSA –  Funding Postgraduate Studies 

Patrick Naughton, MLSA Treasurer


16:00-16:15 Couch Panel: How COVID-19 has impacted the lives of early career Medical Scientists


16:00-16:05 Clinical Placement during COVID-19 pandemic

Clíona O’Shea, Medical Scientist, Molecular Microbiology, CHI at Crumlin

Cliona qualified as a Medical Scientist from CIT/UCC 2020

16:05-16:10 Experiences as a PhD student in CIT and as a medical scientist (MUH) since March 2020.

Caoimhe Lynch, Medical Scientist, Haematology, MUH, Cork & PhD Candidate in Microbiology with a focus on Campylobacter, CIT.

B.Sc (Hons) Biomedical Science graduate (2015), Diploma in Clinical Laboratory Practice – Cork University Hospital (CUH) (2016). Worked as a medical laboratory assistant and medical scientist in the Haematology Dept. of CUH. Returned to Cork Institute of Technology (CIT) in 2017 to start a PhD centred on Campylobacter spp. under the supervision of Professor Aidan Coffey and Dr. Brigid Lucey, funded by the Department of Agriculture Food and the Marine on a Teagasc Walsh Fellowship. Began working as a medical scientist in the Haematology Department of the Mercy University Hospital (MUH) at the end of March 2020. Continuing work on the PhD throughout lockdown.

16:10-16:15 An insight into the life of a biomedical science intern at Cork University Hospital during the COVID-19 Pandemic

Niamh Walsh, Clinical Placement Student, CIT/CUH. Biomedical Science Intern Cork University Hospital.

Niamh Walsh is currently completing a Diploma in Clinical Laboratory Practice in Cork University Hospital. She has recently graduated from Cork Institute of Technology and University College Cork with a degree in Biomedical Science. She has just completed her rotation in the Microbiology laboratory which began on the 7th September 2020. She will be speaking about her experience to date working in a hospital laboratory as a student during this pandemic in particular about her time in the Microbiology laboratory.

16:15-16:20 Mentors Programme – Expression of Interest for Mentees

Hayley Foy-Stones, Medical Scientist / Chair of Engagement and Advancement Advisory Body

Medical Scientist, St James Hospital & Chair of Engagement and Advancement Advisory Body. Chair of the Engagement & Advancement Advisory Body with the ACSLM. This Advisory Body was established in 2019 to focus on the advancement of Medical Scientists in Ireland. Hayley works as a Medical Scientist in Haematology, including the specialised area of Stem Cell and Bone Marrow Transplantation.

Hayley will present the Mentors Programme update on behalf of the Engagement and Advancement Advisory Body. National call for Mentees to complete Expression of Interest Questionnaire

16:20-16:30 Live Panel Q & A

2nd December

Click to register

Chair: Maria Molloy, Laboratory Manager, University Hospital Galway


11:00-11.30 Update on COVID-19. Q&A session

Dr Michael Ryan, Executive Director, WHO Health Emergencies Programme

Dr Mike Ryan has been at the forefront of managing acute risks to global health for nearly 25 years. He served as Assistant Director-General for Emergency Preparedness and Response in WHO’s Health Emergencies Programme from 2017 to 2019.

Dr Ryan first joined WHO in 1996, with the newly established unit to respond to emerging and epidemic disease threats. He has worked in conflict affected countries and led many responses to high impact epidemics. He is a founding member of the Global Outbreak Alert and Response Network (GOARN), which has aided the response to hundreds of disease outbreaks around the world. He served as Coordinator of Epidemic Response (2000-2003), Operational Coordinator of WHO’s response to the SARS outbreak (2003), and as WHO’s Director of Global Alert and Response (2005-2011),

He was a Senior Advisor on Polio Eradication for the Global Polio Eradication Initiative from 2013 to 2017, deploying to countries in the Middle East.

He completed medical training at the National University of Ireland, Galway, a Master’s in Public Health at University College Dublin, and specialist training in communicable disease control at the Health Protection Agency in London and the European Programme for Intervention Epidemiology Training.


11:30-12:00 Sars-CoV-2:  a year is a long time in Virology!

Dr Cillian De Gascún, Director of National Virus Reference Laboratory

Cillian De Gascun is a consultant virologist who graduated from Trinity College Dublin in 1998.  He undertook his basic medical training in Dublin and Brisbane, returning to Dublin in 2002, and completed his specialist virology training in the National Virus Reference Laboratory (NVRL) at University College Dublin (UCD) and Bart’s & The London NHS Foundation Trust in London.  He is a Fellow of the Royal College of Physicians of Ireland (FRCPI), a Fellow of the Royal College of Pathologists in the UK (FRCPath) in Virology, and a Fellow of the Faculty of Pathology of the RCPI.  His MD was awarded in 2011 by UCD for work carried out in the NVRL under the supervision of Professors William Hall and Colm Bergin.  The primary focus of the MD was to describe the molecular epidemiology of HIV-1 in Ireland, but the work also documented the prevalence of antiretroviral transmitted drug resistance in Ireland over a five-year period (2004 – 2008).  Following two years spent as a consultant virologist with Surrey Pathology Services in the UK, Cillian was appointed Director of the National Virus Reference Laboratory and returned to Ireland permanently in 2013.  His main research interests continue to be in the area of the molecular epidemiology of viruses, antiviral resistance, vaccine-preventable infections, and the utilisation of these data to inform national health policy.  In January 2020, Cillian was asked to chair the SARS-CoV-2 Expert Advisory Group, a subgroup of the National Public Health Emergency Team.

In just over 10 months, the world has gone from the publication of the genetic sequence of a novel coronavirus with pandemic potential to the publication of preliminary data from three phase 3 clinical trials for different vaccine candidates against that noel pathogen.  From bats and pangolins to possible vaccine-escape mutants in mink, this presentation will provide an overview of the 2020 SARS CoV 2 pandemic from the virologist’s perspective.

12:00-12:30 SARS-CoV-2 testing in a Paediatric Setting: A CHI at Crumlin Experience

Dr. Adele Habington, Chief Medical Scientist, Molecular Laboratory, Childrens Health Ireland (CHI) at Crumlin.

I grew up in Brisbane, Australia and was awarded my Bachelor of Science in Microbiology from the University of Queensland in 1994. When I was 21 I moved to Dundee, Scotland and studied for my Doctor of Philosophy. My project was titled ‘Investigation of the role of PEBV RNA2 5’ noncoding sequences in RNA replication and protein expression.’ My PhD work was mainly molecular based and gave me an excellent start in this area. In 1998 I moved to Dublin where I worked in the National Children’s Research Centre at Our Lady’s Children’s Hospital Crumlin studying Campylobacter upsaliensis. Then in 2002 I moved 50 metres away to the Microbiology Laboratory at Crumlin Hospital and did my 1 year in-service training to allow me to work as a Medical Scientist in Microbiology. I have worked in the Microbiology Department in CHI at Crumlin ever since, moving into the area of Molecular testing as a Senior Medical Scientist in 2007. In 2016 I became the Chief Medical Scientist in the Molecular Microbiology section of the Microbiology Laboratory overseeing PCR and serology testing in the laboratory.

Background:The provision of a robust testing system for the detection of Sars-CoV-2 in respiratory samples is an important component in the management of hospital patient and staff in the current pandemic. The lack of availability of sufficient rapid PCR testing cartridges has meant that the focus of PCR testing is primarily in the area of the higher throughput but slower batch based PCR testing.
The groups of patients who require testing are patients exhibiting respiratory symptoms and pre-operative patients who are undergoing procedures which may generate aerosols. Staff testing is also performed on-site and this facilitates rapid contact tracing and permits the return of staff to work.
Aim: Our aim was to provide a batch based PCR system for the testing of samples for Sars-CoV-2.
Methods: The initial method of choice was based on the equipment already available in the Molecular Section of the Microbiology Laboratory. The method consisted of sample lysis, sample extraction using the QIAsymphony SP, followed by real-time PCR using the Anatolia Geneworks Bosphore PCR kit and the ABI FAST PCR system. Initially, test validation was performed using positive sample panels from the National Virus Reference Laboratory and External Quality control samples. In June 2020, an additional testing system was added, the Seegene All-In-One Platform. Both of these testing systems take between 5-6 hours from sample to result.
Results: Since March 25 2020, the Molecular Microbiology has been providing a testing service for Sars-CoV-2 detection in respiratory samples of patients and staff. Over 6000 samples were tested by November 2020, with a positivity rate of 1.98%

Click here to register


Chair: Sinéad Creagh, Laboratory Manager, Cork University Hospital

13:00-13:30 A Systematic Analysis of laboratory-Guided Diagnosis and Management of COVID-19: Challenges and Recommendations

Shane Whelan, Department of Biological Sciences, CIT Cork


13:30-14:00  Tallaght University Hospital Antibody Study

Caroline Murray, Senior Medical Scientist, Tallaght University Hospital and Phyllis Reilly, Senior Medical Scientist, Tallaght University Hospital

Caroline Murray – Senior Medical Scientist, Tallaght University Hospital. Phyllis Reilly, Senior Medical Scientist, Tallght University Hospital. Caroline graduated from UCC/CIT Biomedical Science in 2008 and completed her training in Waterford University Hospital, where she worked in Biochemistry and Haematology labs for 2 years before moving to Biochemistry/Metabolic labs in Temple St Children’s University Hospital in 2011. She completed the MSc in Clinical Chemistry in 2015 through TCD and started as Senior Medical Scientist in Clinical Chemistry, Tallaght University Hospital in 2017.

Phyllis graduated from Dublin Institute of Technology Biomedical Science in 2009 majoring in Clinical Chemistry. Phyllis began working as a medical scientist in the Clinical Chemistry laboratory Tallaght University Hospital in 2010. She completed the MSc in Clinical Chemistry in 2016 through TCD. She began working as a Point of Care Medical Scientist in the Laboratory Medicine Department Tallaght University Hospital in 2016 and started working as a Senior Medical Scientist in the Clinical Chemistry department Tallaght University Hospital in 2018. Caroline and Phyllis are an integral part of the TABS team and played a pivotal role in the completion of Phase 1 of the project. They used their extensive method verification knowledge to aid in the development of the anti-SARS-CoV-2 service as well as the overall study design and implementation. Both ladies are now heavily involved in Phase 2 of TABS as well as a number of other key research projects in the Laboratory Medicine Innovation Hub at TUH led by Dr Ann Leonard, Professor Gerard Boran and Dr Anna-Rose Prior.

Since the onset of the COVID-19 pandemic, healthcare workers are generally considered at higher risk of SARS-CoV-2 exposure and infection acquisition than the general population. Phase 1 of this study aimed to evaluate SARS-CoV-2 seroprevalence in healthcare workers (HCWs) in Tallaght University Hospital and correlate seroprevalence with known or suspected SARS-CoV-2 infection in this population since the onset of the pandemic.

 Click to register

Chair: Karen Hickey, Senior Medical Scientist, Microbiology Laboratory, Sligo University Hospital

15:00-15:30 Diagnostic accuracy of Gram stain (Hay’s criteria) against BV PCR for diagnosis of bacterial vaginosis

Thomas Murphy, Medical Scientist, Rotunda Hospital.

Medical Scientist, Rotunda Hospital. I am from Portrane, North County Dublin. I started out as a Medical Laboratory Assistant in Cappagh Hospital in 2013. In 2014, I worked as a Medical Laboratory Assistant in the Rotunda Hospital and from here I qualified as a Medical Scientist in March 2017. I have been working in the Rotunda Hospital as a medical scientist ever since. I recently completed my Msc. and my project was on comparing the Seegene analyser versus gram stain for diagnosing BV.

BV can cause complications in pregnant women that include; low birth weight, premature rupture of membranes and chorioamnionitis. Diagnosis is by Gram stain of a vaginal smear based on Hay’s criteria. The main problem with this method is the inter- rater reliability of interpreting the Gram stain among scientists. The Seegene Allplex BV panel is a multiplex real-time PCR assay that can be used for the quantitative/qualitative detection of bacteria that cause BV. 200 Gram stain impressions from high vaginal swabs were made and then inoculated into the liquid medium for PCR and then analysed. The results of both methods were compared. Lactobacilli were more commonly identified in normal swabs, where AV and GV were associated with BV. The use of PCR will eliminate the inter- variability of gram stain results. This study has showed that using BV PCR is a viable alternative for diagnosis of BV.


15:30-16:00 Establishment of the prevalence of Mycoplasma genitalium and its associated macrolide resistance in the South East of Ireland and evaluation of two Real Time-PCR assays

Laura Johnson, Medical Scientist, University Hospital Waterford.

Mycoplasma genitalium is a sexually transmitted organism found primarily in the urogenital tract. It is a recognised cause of urethritis in men and is associated with pelvic inflammatory disease in women.  Marcolide antibiotics such as azithromycin, have long been used as the first line treatment for this infection, however this treatment is becoming less effective due to increasing resistance. Traditional culture of this organism from clinical samples is not routinely performed due to the extremely fastidious and slow growing nature of Mycoplasma genitalium.  Use of nucleic acid amplification testing offers a viable diagnostic solution for the detection of Mycoplasma genitalium in routine laboratories. As currently Mycoplasma genitalium testing is only available from the national reference laboratory all at risk patients are not tested, treatment is empirical and the true prevalence is unknown. In this study two Real Time-PCR assays, the SpeeDx Resistance® Plus MG and the TIB MOLBIOL- LightMix® Kit Mycoplasma genitalium (EC) were evaluated on the fully automated Roche LC480II LightCycler® to detect Mycoplasma genitalium. Positive samples were then further evaluated for macrolide resistance and a comparative analysis was performed between each RT-PCR assay.

Click here to register

19:00-20:00 – The virology of COVID-19 (Video)

Dr. Brendan Crowley, Consultant Microbiologist, St James Hospital, Dublin

3rd December

Click to register

Chair: Dr. Fidelma Hernon, Senior Medical Scientist, Blackrock Clinic 

11:00-11:30 Whole Genome Sequencing: Diagnostic Friend or Foe?

Dr Peter Flanagan, Clinical Scientist, Irish Mycobacterium Reference Laboratory, St. James’s Hospital and Visiting Fellow – TCD.

11:30-12:00 Microarray-based Epigenetic Classifier for Brain Tumours

Teresa Loftus, Senior Medical Scientist, Beaumont Hospital

I am a Specialist Medical Scientist in the Molecular Laboratory in Beaumont Hospital. Having completed an MSc in Molecular Medicine from Trinity College Dublin, I became a Fellow of the Academy of Clinical Science and Laboratory Medicine (ACSLM), and sit on the advisory board for Molecular Diagnostics for the ACSLM. I am a quality assessor for the Central Nervous System Cytogenomic External Quality Assurance Scheme (CEQAS). Recently Beaumont Hospital embarked on a laboratory modernisation project which included upgrading the molecular facility. This involved overseeing the move of all instrumentation to the newly located laboratory and the revalidation of all instrumentation and assays to the ISO15189 international standard.

Beaumont Hospital is the national referral centre for all Paediatric and Adult molecular neurooncology. We perform an array of assays, including techniques such as real time PCR, pyrosequencing, array comparative genomic hybridization and Next Generation Sequencing. In 2019 we set about introducing DNA methylation profiling within the department.

DNA methylation profiling of brain tumours has proven to be very useful in the medical setting in recent years. It has important diagnostic, prognostic and treatment implications. It was set up in the Molecular lab in Beaumont Hospital in 2019 to facilitate the needs of paediatic and adult neurooncology patients. Using this technology, the data generated is analysed to determine a tumour classification, copy number profile and MGMT methylation result.

Click to register

Chair: Fergus Guilfoyle, Chief Medical Scientist, Coombe Women and Infants University Hospital.

13:00 – 13:30 The identification and management of Anti-Jk3 in pregnancy

Cait Geaney, Senior Medical Scientist, Red Cell Immunohaematology Laboratory, Irish Blood Transfusion Service, James’s St. Dublin 8

Since graduating from D.I.T in 2009, Cáit worked in Crumlin Transfusion and Haematology Laboratory’s for 3 years and worked in a Medical and Pharmaceutical Laboratory’s in Melbourne, Australia for 4 years. Since returning from Australia she has worked in the Irish Blood Transfusion Service. She completed an MSc in Biomedical Science (2018) which focused on antenatal testing in the Red Cell Immunohaematology Laboratory.  Cáit is a Senior Medical Scientist in charge of antenatal testing in the RCI laboratory and rare reference cell co-ordinator. Today she will present a recent case where anti-Jk3 was detected in a pregnant patient.

The Kidd-null phenotype Jk(a-b-) occurs in individuals who do not express the JK glycoprotein. The Kidd blood group system contains three antigens: Jka, Jkb and Jk3. Anti-Jk3 is a high incidence antigen present in more than 99.9% of populations. Jk(a-b) individuals can make an antibody against the Jk3 antigen. Jk(a-b-) is the rare null phenotype commonly found in Polynesians. Kidd antibodies may cause acute and delayed haemolytic reactions as well as haemolytic disease of the fetus and newborn (HDFN).

We present a case of a pregnant 45 year old female where anti-Jk3 was identified.  The process of antibody identification, antibody titration throughout her pregnancy will be discussed. In addition the complexity of trying to source blood for this patient; targeted screening of the Irish donor population and importation of blood from the European Union to cover delivery.
Results: On initial workup the patient grouped as ORhD positive a historical red cell phenotype was available C+ E- c- e+ M+ S- s+ K- Fy(a+b-) Jk(a-b-). Pan reactivity was observed by the indirect antiglobulin test (IAT) and by enzyme-IAT technique.  Using rare Jk (a-b-) cells from the RCI repertoire of rare reference cells negative reactions were obtained.  To ensure there were no other clinically significant antibodies detectable adsorption techniques were performed. Throughout her pregnancy antibody titrations were performed.  Titrations are performed using the Kidd phenotypes: Jk(a-b+), Jk(a+b-) and Jk(a+b+) to indicate the requirement for Fetal Medicine Specialist unit referral.
Conclusion: The provision of blood for these patients does require importation of units if suitable blood cannot be sourced in the country. Jk3- negative people are most likely to be found in Polynesians, South East Asians and Finns. Liquid donations and frozen units from the bank were sought to cover delivery. Siblings of patients with anti-Jk3 should be tested for compatibility and the patient also and patients are urged to donate blood for cryogenic storage.

Click here to register


James Harte, CIT/UCC

Biographical detail
James Harte is a graduate of the BSc (Honours) in Biomedical Science from CIT/UCC. James achieved a first-class honours ranking at third-level, consistently scoring highest in his class and was recognised as the ’Best Honours Degree Student’ in BSc (Honours) in Biomedical Science and ’Best Honours Degree Student’ in the School of Science and Informatics at Cork Institute of Technology. During his time as an undergraduate, this recognition was documented by several nominal honours including successive ‘College Scholar’ titles for achieving first-class honours, successive ‘Faculty Scholar’ titles for ranking first-in-class, and three, highly prestigious ‘Quercus College Scholarships’ for exceptional examination results. In 2017, James was awarded the highly competitive ‘Quercus University Scholarship’ for consistent academic excellence, a distinction bestowed on a single student each year. His curiosity for scientific endeavour has also driven an extraordinary engagement with academic research, including experience as a research assistant in the Centre for Research in Advanced Therapeutic Engineering at CIT; one-of-eight APC Microbiome Institute Summer Studentships, conducting an independent metagenomic project; a research survey into antimicrobial resistance in Ireland, which is currently in preparation for publication, and one-of-twenty distinguished Europe-wide Amgen Scholarships, which supported intensive research at the University of Cambridge. His final year project, under the supervision of Dr. Justin McCarthy at University College Cork, characterised the sequential proteolysis of a novel gamma-secretase substrate. Subsequently, he was retained as a research intern to continue aspects of the characterisation, and his experimental data will form part of a forthcoming publication. In addition to his avidity for science, James has a keen interest in teaching and learning. He has been a tutor at first-, second-, and third-level for many years, fastening his abiding love for science with community engagement. As a tutor, James takes pride and pleasure in distilling complex concepts into their most basic components, and has taught several undergraduates fundamental and advanced laboratory skills during his time as a research intern at University College Cork. James also engaged in a variety of recognised student activities, including standing as the academic representative for his year group, writing articles for the UCC Express in Irish and in English, partaking in societal offices, and speaking at student-focused events. His engagement with the profession of medical science has been pivotal in hammering and forging James’ personality. He holds three axiomatic principles close to his heart: the pursuit of personal development and identity; the pursuit of professional development and higher education; and the pursuit of life-long happiness. As he embarks on the next stage of his journey, he hopes to continue to challenge himself at every possible level, to advance his own knowledge and understanding of medical science, and hopefully, to contribute to the ever-expanding field of medical research in a way which is beneficial to the greater population as a whole.


DISCIPLINE: Clinical chemistry

 AUTHORS: Harte, J.V.1,2, McCarthy J.V.3
Department of Biological Sciences, Cork Institute of Technology, Rossa Avenue, Bishopstown, Cork, Ireland.
School of Biochemistry and Cell Biology, University College Cork, College Road, Cork, Ireland.
3 Signal Transduction Laboratory, School of Biochemistry and Cell Biology, ABCRF, 3.41 Western Gateway Building, Western Road, University College Cork, Cork, Ireland.

 Introduction: The renin-angiotensin system (RAS) is a critical component of the response to hypovolaemia and hypotension; however, RAS dysfunction is an appreciable mechanism of disease1. The recently discovered angiotensin-converting enzyme 2 (ACE2) is known to counterregulate the potentially destructive effects of uncontrolled angiotensinergic activity2. Subversion of ACE2 by pathophysiological conditions, including infection by zoonotic coronaviruses, can contribute to inappropriate activation of the RAS and accentuate inflammatory and fibrotic disease. Although ACE2 is known to undergo ectodomain shedding, a feature shared by many substrates of γ-secretase-dependent regulated intramembrane proteolysis3, no studies have investigated the subsequent cleavage of the ACE2 carboxyl-terminal fragment (CTF).

Materials and Methods:
 The molecular mechanism of ACE2 cleavage following ectodomain shedding was investigated by Western blot analysis in cultured cells expressing exogenous or endogenous ACE2 using pharmacological inhibitors and genetic deficiency of presenilin. The subcellular localization of γ-secretase-dependent proteolysis was also investigated using inhibitors of clathrin-dependent endocytosis.

 In this study, we show that following ectodomain shedding, the membrane-bound ACE2 CTF is subsequently cleaved by γ-secretase, and that specific biochemical and genetic loss of γsecretase activity independently compromise sequential cleavage of ACE2. Pharmacological inhibition of proteasomal degradation also revealed a putative γ-secretase generated ACE2 intracellular domain (ICD). Moreover, we show that clathrin-mediated internalization of ACE2 is necessary for γ-secretase-dependent proteolysis.

 These observations demonstrate that ACE2 is a novel γ-secretase substrate and the formation of a potentially biologically active intracellular domain may be partly responsible for the counter-regulation of the “classical” RAS. Internalization-dependent cleavage may also partly explain the uptake of zoonotic coronaviruses. Thus, the identification of ACE2 as a γ-secretase substrate may facilitate translational approaches for manipulating RAS activity in vivo, with potential biomedical significance in terms of health and disease.

1. Forrester S, Booz G, Sigmund C, Coffman T, Kawai T, Rizzo V, et al. Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology. Physiological Reviews. 2018;98(3):1627-1738.
2. Paz Ocaranza, M, Riquelme, J, García, L, et al. Counter-regulatory renin–angiotensin system in cardiovascular disease. Nature Reviews Cardiology. 2020;17(2):116-129.
3. McCarthy, A, Coleman-Vaughan, C, and McCarthy, J. Regulated intramembrane proteolysis: emergent role in cell signalling pathways. Biochemical Society Transactions. 2017; 45(6); 1185– 1202.


Clodagh Lalor, GMIT

Biographical Detail
I successfully graduated with a BSc. in Medical Science from GMIT and completed my placement in University Hospital Limerick (UHL). Following this, I took a keen interest in Clinical Chemistry and worked in the Biochemistry Dept. as a student medical scientist and further completed a final year project in the laboratory. I majored in Clinical Chemistry and Medical Microbiology in 2019 after which I began working in the Biochemistry Laboratory, UHL and I am working there to this day.



 Discipline: Clinical Chemistry

Authors: (1) Lalor C, McGrath M, Conmy B.

(1) Riversdale, North Circular Road, Limerick.

Institution: Dept. of Biochemistry, University Hospital Limerick in collaboration with Dept. of Biopharmaceutical and Medical Science, Galway-Mayo Institute of Technology.

Introduction: Faecal calprotectin (FC) is a routinely used, non-invasive biomarker for the diagnosis and monitoring of Inflammatory Bowel Disease (IBD) [1]. The primary aim of this study is to evaluate the Bühlmann fCAL faecal calprotectin turbo assay in order to bring FC testing into routine testing on site in University Hospital Limerick (UHL).

Material and Methods: The performance characteristics of fCAL turbo assay were verified on the Abbott Architect C16000 analyser. Precision was carried out by analysing two levels (low and high) of Internal Quality Control (IQC) in three replicates, daily for five days. Accuracy was measured by analysing nine EQA samples. Additionally, a comparison study was performed which involved the measurement of 20 patient samples on both the Abbott Architect C16000 and Phadia 250 instrument.

Results: The precision study confirmed consistency with the manufacturer’s claims and revealed a total coefficient of variation (CV) of 1.53% and 3.8%, respectively. A high percentage inaccuracy of 21.83% and significant negative bias was observed for accuracy studies. A percentage bias of 88.9% and Passing-Bablok analysis revealed poor agreement between the two methods, further emphasised by a p value of 0.007 (α=0.05). The null hypothesis was thereby rejected.

Conclusion: The fCAL turbo assay performed in accordance with the manufacturer’s specifications of precision. However, accuracy and method comparison results were unsatisfactory for the verification of the assay. Further analysis is required before introduction of the assay into routine testing. Once the analytical performance is evaluated successfully, the assay will be implemented on site, drastically reducing turnaround times, decreasing referral costs and improving service to users.

References:  [1] Seenan JP, Thomson F, Rankin K, Smith K, Gaya DR. Are we exposing patients with a mildly elevated FC to unnecessary investigations? Frontline Gastroenterology. 6th ed. 2015; 156-160.


Ciara Liptrot, GMIT

 Biographical Detail
I studied Medical Science at the Galway Mayo Institute of Technology graduating in November 2019. In my final year of study I chose to specialise in Haematology, Blood Transfusion and Cellular Pathology. Throughout college blood transfusion and haematology were my favourite modules. I was fortunate to have had the opportunity to carry out my final year research project in the Red Cell Immunohaematology laboratory (RCI) at the Irish Blood Transfusion Services. Here I began my career as a medical scientist and got to see aspects of my research project validated and adopted into routine practice. Working in the RCI laboratory, I gained great Blood Transfusion knowledge and experience. I have recently begun working in the Coombe Women and Infants University Hospital Haematology and Transfusion laboratories where I hope to further develop my Haematology knowledge and Blood Transfusion expertise.


Improving the Process of Mitigating Daratumumab Interference in Pre-transfusion Compatibility Testing

Liptrot, C., Cregg, H., Scally, E.

Galway-Mayo Institute of Technology, Old Dublin Rd, Galway

Irish Blood Transfusion Services, National Blood Centre, St. James’s Street, Dublin 8

Transfusion and Transplantation Science

Multiple myeloma (MM) is a malignant plasma cell disorder. Daratumumab (DARA), a monoclonal antibody directed against CD38, may be used for the treatment of MM as CD38 is over expressed on the malignant plasma cells¹. Treatment with DARA, however, interferes with pre-transfusion compatibility testing as DARA binds CD38 on reagent red cell. Several methods may be utilised in order to mitigate DARA interference including DTT treatment of reagent cells and masking CD38 present on reagent-cells. The aim of this research was to improve the current process of mitigating interference due to DARA in pre-transfusion compatibility testing.

The utility of extending the shelf life of DTT-treated reagent red cells was assessed.   Batch DTT-treated reagent red cells remained stable for up to 28 days post treatment. However, based on this study, due to haemolysis of cells and a decrease in reaction strength of some red cell antigens by day 28, the shelf-life of DTT-treated cells should be extended no longer than 14 days.

The validity of a room temperature crossmatch for patients who have been administered DARA and have a negative antibody screen was also assessed. Using NaCl gel cards, 22 patient plasma samples containing DARA were crossmatched against group O Rh D negative donor cells with compatible reactions observed.  The implementation of a room temperature crossmatch would eliminate the need to DTT-treat donor red cells for compatibility testing and thus reducing laboratory turnaround-times.

The efficacy of DaraEx, an anti-CD38 neutralizing agent was evaluated. The ability of DaraEx to inhibit DARA interference was found to be dependent on the amount of DARA circulating in patient plasma and possibly the number of CD38 antigenic sites on reagent cells. An advantage of the use of DaraEx-treated reagent-cells, in comparison to the DTT based method of pre-transfusion compatibility testing for this patient group, is that DaraEx-treated cells may be used for the detection of anti-K.


  1. Chapuy, C., Aguad, M., Nicholson, R., AuBuchon, J., Cohn, C., Delaney, M., Fung, M., Unger, M., Doshi, P., Murphy, M., Dumont, L. and Kaufman, R. (2016). International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing. Transfusion, 56(12), pp.2964-2972.


Áine O’Connor, TU Dublin

Biographical Detail

I achieved a first class degree honours in Biomedical Science (BSc) from TU Dublin- City Campus in 2019. I completed a translational research project in Karolinska Institutet Sweden for my undergraduate thesis, analysing the regenerative potential of human placental amnion epithelial cells. I am currently working in a fast paced clinical lab setting in Tallaght hospital.



In Vitro Expansion of Human Placental Amnion Epithelial Cells.

Aine K. O’ Connor

 Transfusion and Transplantation Science
 Karolinska Institutet Flemingsberg
Trevet Grange Dunshaughlin Co. Meath 

O’ Connor, AOC., Brankin, BB., Gramignoli, RG.

Liver failure represents a major public health concern worldwide. According to the World Health Organisation, the total deaths caused by cirrhosis and liver cancer have increased by 50 million/ year since 1990 (1). Until recently orthotopic liver transplantation (OLT) has remained the only established curative therapy for treating acute, chronic liver disease or metabolic defects in liver function. However, organ donor availability remains one of the main constraints on health services.  Over the past 3 decades, cell-based therapies have been gaining importance since they can contribute to regeneration of failing organs or damaged tissues by either direct replacement of the lost cells or by facilitating the body’s natural regenerative processes. Hepatocyte transplants (HT) have been gaining recognition as an alternative therapeutic option, although it is limited by the need for strict immunosuppressive therapy in support of long-term engraftment. Furthermore, allograft rejection remains a primary issue that prevents the long-term sustained therapeutic benefits of HT (2)

The placenta, or specifically the amniotic epithelial (AE) cells are a promising non-controversial source of potential stem cells. Their constitutive ability to mature into different cell types and correct life threatening liver disease in preclinical models have highlighted them as a potential candidate for liver-based therapy. Ex vivo expansion of AE cells may be important to generate an adequate yield for transplantation, in addition to reducing the number of allogenic donor AE cells per recipient. We isolated AE cells from six gestational full term placentas which generated high amounts of cells (up to 240 million of AE cells per placenta) characterised by high viability (91.5 ± 3.4 %). Whilst preserving several of their native characteristic features, we successfully expanded AE cells in a xenobiotic-free culture medium (PneumaCult™) supplemented with human platelet lysate in comparison to the current gold standard medium formulation. Our results showed AE cells proliferated robustly in PneumaCult™. Gene expression analysis by qRT-PCR showed expanded AE cells maintained their native epithelial marker expression (CD326 and cytokeratin 18). Using albumin ELISA quantitation AE cells secreted albumin upon expansion, albeit at levels equal to half of what is observed in healthy hepatocytes. Focusing on the wider clinical application of AE cells, it could be envisaged from these results that AE cells may aid in expanding the donor hepatocyte pool, generating functionally improved hepatocytes without the need to increase hepatocyte donor source.


  1. Murray, C. and Lopez, A. (2013). Measuring the Global Burden of Disease. New England Journal of Medicine, 369(5), pp.448-457.
  2. Iansante, V., Mitry, R., Filippi, C., Fitzpatrick, E. and Dhawan, A. (2017). Human hepatocyte transplantation for liver disease: current status and future perspectives. Pediatric Research, 83(1-2), pp.232-240


Cliona O’Shea, CIT/UCC 

Biographical Detail
My name is Clíona O’ Shea. In 2019 I graduated with a first class honours joint Biomedical Science degree from Cork Institute of Technology and University College Cork (CIT/UCC). I completed my 5th year clinical laboratory placement in the Mercy University Hospital (MUH) in Cork City. My laboratory research project, in the MUH microbiology laboratory, aims to establish whether the reporting of Uncertainty of Measurement estimates for antibiotic susceptibility testing using the disc diffusion method is a necessity in the clinical microbiology laboratory. I am an enthusiastic, diligent and reliable person who is self-motivated and who enjoys working with others. I love being part of the team in a clinical laboratory and wider hospital and I believe in and value our profession. To give a small example, I recently aimed to educate MUH laboratory staff at a multi-disciplinary journal club on continuous professional development (CPD) and reflective practice for medical scientists. I am excited to start my career as a medical scientist. I am privileged and honoured to be a part of the President’s Prize competition at Biomedica 2020. I will be presenting on my final year research project which is titled ‘Investigation of the ability of the bacteriocin nisin to inhibit coagulase negative Staphylococci’. I am currently working as a medical scientist in CHI at Crumlin.


Investigation of the ability of the bacteriocin nisin to inhibit coagulase negative Staphylococci

O’ Shea, C.,Twomey, E., Field, D., Begley, M.
Department of Biological Sciences, Cork Institute of Technology

Introduction: Coagulase negative Staphylococci (CoNS) are ubiquitous colonizers of human skin (1). While previously seen as harmless commensals, CoNS are now viewed as opportunistic pathogens and are reported to be the leading cause of infections related to implanted medical devices (2). Of particular concern, is the increasing development of resistance to conventional antibiotics. Furthermore, CoNS can form biofilms that aid adherence to biotic or abiotic surfaces, and biofilms are inherently refractory to treatment with antibiotics (3). As the number of medical device implantation surgeries is projected to increase, owing to the ageing population and improving healthcare in developing countries, alternative approaches to control CoNS are therefore urgently required. The present study investigates the ability of the natural microbially-produced peptide bacteriocin nisin to inhibit CoNS.

Materials and Methods: A bank of commensal and clinical CoNS was assembled, and strains were characterized using a variety of standard microbiological and biochemical tests. The ability of the strains to form biofilm was examined using a standard plastic microtiter plate-based assay. Agar-based deferred antagonism assays were employed to assess whether CoNS were inhibited by a nisin producing bacterium. Nisin peptide was purified from the nisin producer by reversed-phase high performance liquid chromatography (RP-HPLC), and minimum inhibitory concentration assays were carried out. The microtiter plate-based assay was employed again to assess how nisin affected biofilm formation on plastic surfaces. Subsequent experiments of this study focused on optimizing a method to examine biofilm formation by CoNS on a medical device substrate i.e. stainless steel.

Results: All of the CoNS strains in this study were shown to form biofilm, however the extent of biofilm formation varied between strains, as determined by final optical densities of crystal violet stained biofilms. It was observed using the agar-based deferred antagonism assays, that a nisin producing bacterium had the ability to inhibit the growth of all CoNS. The minimum inhibitory concentration of nisin against the tested CoNS strains was shown to be in the micromolar (μM) range. The addition of nisin during microtiter plate-based assays resulted in a significant reduction of biofilm formation. Furthermore, biofilm formation on stainless steel was also shown to be significantly reduced in the presence of nisin.

Conclusion: In summary, this study reports the ability of nisin to inhibit a bank of CoNS and their ability to form biofilms. Nisin may ultimately be used to develop novel coatings for medical devices, or be impregnated into them, with the aim of reducing the incidence of or preventing, medical device related infections caused by CoNS.


  1. Otto, M. 2009. Staphylococcus epidermidis – the “accidental” pathogen. Nat. Rev. Microbiol. 7:555-67.
  2. Campoccia D., Montanaro L., and Arciola C.R. The significance of infection related to orthopaedic devices and issues of antibiotic resistance. Biomaterials 27:2331-9.
  3. McCann M., Gilmore B.F. and Gorman S.P. Staphylococcus epidermidis device-related infections: pathogenesis and clinical management. J. Pharm. Pharmacol. 60:1551-71.


Natalia Unrath, TU Dublin

Biographical Detail
I graduated from TU Dublin in 2019 with a BSc in Biomedical Science. I started my career in the microbiology department in Connolly Hospital. I am currently pursuing a PhD in the Centre for Food Safety, University College Dublin where I am specialising in the use of Whole Genome Sequencing to assess the virulence and persistence potential of Listeria monocytogenes under the principal supervision of Professor Séamus Fanning.



Medical Microbiology.

UCD-Centre for Food Safety, School of Public Health, Physiotherapy and Sports Science, Science Centre South, University College Dublin, Belfield, Dublin D04 N2E5.

Unrath, N., McCabe, E., Hurley, D., Herra, C., Fanning, S.

Listeria monocytogenes is the etiological agent of listeriosis, a foodborne illness associated with high hospitalization and mortality rates.(1) L. monocytogenes may be classified as hypovirulent, intermediate and hypervirulent, based on the presence of Listeria pathogenicity islands (LIPIs).(2) This bacterium can exist in food associated environments for years with persistent strains being linked to outbreaks of foodborne disease.(3) This study aimed to improve food-borne subtyping and identification of virulent and persistent L. monocytogenes in food associated environments through the application of whole genome sequencing (WGS).

WGS was applied to a collection of 143 L. monocytogenes from a longitudinal study of a large food production facility, collected between 2014 and 2017. Sequence data was analysed using bioinformatic tools. Virulence was assessed using the Virulence Factor Database (VFDB). Persistent strains were detected using multilocus sequence typing (MLST) in silico, single nucleotide polymorphism (SNP) analysis and the determination of biocide resistance using the BacMet database.

The assessment of virulence profiles revealed that only one isolate was hypovirulent and two others were hypervirulent, with the majority (98%) being intermediate. In silico MLST and SNP analysis showed that 77% of the isolates are potential persisters and harbor resistance genes to biocides commonly used in food environments. These findings suggest that virulent L. monocytogenes are present and persisting within Irish food environments which can have adverse effects on both the food producer and public health.

WGS can achieve more than just discrimination between unrelated isolates. An additional benefit of WGS is the opportunity to extract specific information, such as, the determination of virulence, antibiotic or biocide resistance status, as well as the assignment of serotypes. WGS is the ultimate tool for characterization of bacterial isolates as it provides the highest possible resolution in strain typing and represents a paradigm shift for outbreak investigation and contamination-source tracking.


  • EFSA and ECDC. The European Union One Health 2018 Zoonoses Report. EFSA Journal. 2019;17(12): 5926.
  • Maury MM, Tsai YH, Charlier C, Touchon M, Chenal-Francisque V, Leclercq A, Criscuolo A, Gaultier C, Roussel S, Brisabois A, Disson O, Rocha EPC, Brisse S, Lecuit M. Uncovering Listeria monocytogenes hypervirulence by harnessing its biodiversity. Nature Genetics. 2016;48(3): 308-313.
  • Ferreira V, Wiedmann M, Teixeira P, Stasiewicz MJ. Listeria monocytogenes persistence in food-associated environments: epidemiology, strain characteristics, and implications for public health. Journal of Food Protection. 2014;77(1): 150-170.

4th December

Click to register

Chair: Ciaran Love, Chief Medical Scientist, Cellular Pathology, Tallaght University Hospital

11:00-11:30 Molecular Pathology Testing of Solid Tumours: What happens to the sample in the Molecular Laboratory?

Tony O’ Grady, Chief Medical Scientist, Royal College of Surgeons in Ireland

Tony has worked as a Medical Scientist in Histopathology/Molecular Pathology for over 20 years and has spent most of that time in the department of Pathology at the Royal College of Surgeons in Ireland at Beaumont Hospital. Tony is in charge of a busy Molecular Pathology laboratory providing a referral service to hospitals throughout the country. He has extensive experience of molecular pathology of solid tumours and has acted as an assessor for UK NEQAS for the past 15 years.

Molecular pathology can be broadly defined as the analysis of nucleic acids within a clinical context. Molecular techniques in Pathology can provide a more accurate diagnosis, identify prognostic markers and contribute to the development of novel molecular targets. The molecular analysis of tissue and blood is now routinely used in the diagnosis and sub-classification of many tumours and to predict response to therapies in this era of personalised medicine. There are many nucleic acid sequencing technologies available and the choice of which one to use depends on many factors, particularly the information required and when it is required. In today’s molecular pathology laboratory rapid analysis of small samples is a key requirement. This presentation will take a look inside one such molecular pathology laboratory and describe current methodologies highlighting their clinical utility.

Click here to register

Chair: Dr Brian Moran, Lecturer in Medical Science, GMIT.

13:00-13:30 Radionuclide Imaging of the Thyroid and Parathyroid glands to demonstrate functional and structural pathology

Róisín Bisland, Senior Radiographer & Clinical Practice tutor for UCD radiography students in Naas General Hospital.


13:30-14:00 Infinity and Beyond – Verification of a Clinical Chemistry Data Management System

Leanne Ricciardelli, Senior Medical Scientist, Naas General Hospital.

Leanne graduated with a BA. Mod. in Biochemistry from TCD and subsequently completed a post graduate transition programme to Medical Science and membership to the ASCLM in 2005.  She completed her MSc in Molecular Pathology (Clinical Chemistry) with DIT in 2009. Leanne has been working as a Senior Medical Scientist in Clinical Chemistry in Naas General Hospital since 2010. In her spare time she plays a lot of volleyball and has represented Ireland internationally at both indoor and beach competitions.

Click here to register

Chair: Ciaran Love, Chief Medical Scientist, Cellular Pathology, Tallaght University Hospital

15:00-15:30 Update on Cellular Pathology Working Group on Medical Scientist Role Development

Michelle Griffin, Chief Medical Scientist, Histopathology, Waterford University Hospital

15:30-16:00 Cellular Pathology Skills Review Working Group: Updates

Anna Marie Purcell, Senior Medical Scientist, Mater Misericordiae University Hospital.

19:30 – 19:45 Awarding of the Presidents Prize


20:00 – 21:30 Zoom Quiz with Interval Entertainment: The Heathers

Booking will be through the ACSLM website.
A button “Biomedica Quiz Registration” will be accessible on the home page

Upcoming Webinars

Click here to register

Fluoropyrimidines (FPs), including 5-fluorouracil (5-FU) and its pro-drugs are the most widely used chemotherapeutic agents for many types of solid tumours. Approximately 450, 000 patients in the EU are treated annually with FPs. They have a narrow therapeutic window with a small difference between the minimum efficacious dose and the maximum tolerable dose, with high interpatient variability. These drugs carry up to a 20% risk of Grade 3-5 toxicity and 0.2-1% risk of death, due to dihydropyrimidine dehydrogenase (DPD) deficiency. This is due in large part to the presence of variants in the DPYD gene, which codes for the DPD enzyme. In nature, DPD is responsible for the metabolism of endogenous pyrimidines, including uracil.  DPD also functions as the rate limiting step in the metabolism of FPs.  Thus, while FPs can be highly effective in treating cancer, severe, sometimes fatal, toxicities occur in a significant minority of patients, which represents an important public health problem.  Recently, following a European Medicines Agency recommendation, the HPRA and the National Cancer Control Programme issued recommendations that DPD deficiency testing be carried out on all patients prior to fluoropyrimidine-based chemotherapy. There are several methods available for DPD deficiency testing. These include metabolic tests (dihydrouracil/uracil ratio), genomic tests for various SNIPs or a combination of metabolic and genomic tests. Here we review a combined, multiparametric, approach which integrates metabolic, genomic and physiologic data. This approach has been demonstrated to significantly reduce the rate of false negatives encountered with other methods. It can therefore reduce mortality and morbidity, improve patient outcomes and significantly reduce the costs associated with treatment for toxicity.


  • This multiparametric approach can predict 97.6% of lethal toxicities and 95.49% of severe toxicities to fluoropyrimidines
  • Specific dosage is suggested by CE marked calculator for DPD deficient patients, giving these patients their best opportunity for positive outcomes
  • Cost-benefit is positive – cost of testing all patients is less than treating the toxicities this test avoids
  • PK-guided dose adjustment is available during treatment, also using the CE-marked calculator

Click here to register


Dr Brian Bird

Consultant in Medical Oncology

Dr Michèle Boisdron-Celle

Head of the Biopathology Lab

Integrated Center for Oncology, Angers, France and Co-Founder and President, ODPM

Jamie Cahalane

Business Development Manager Genomics and Speciality Testing

Eurofins Biomnis

Andrew Kenny

Chief Medical Scientist, Biochemistry

Bon Secours Hospital, Cork

Dr Jean-Philippe Metges

Oncologist specialised in digestive cancer, Professor at Cancer and Hematology Institute

Brest University Hospital

Linda Rattner Celle

International Marketing and Operations Director


Click here to register

Saving more than 200 staff days per year by automating embedding with the Tissue-Tek AutoTEC® a120

With challenges increasing in today’s histopathology labs such as staff shortages and increasing cancer numbers, the need to work smarter for faster results and provide higher quality is more important than ever..

Histopathology Labs are starting to change how they do things by embracing the latest technologies for automating repetitive manual processes and achieving greater standardisation, freeing up staff time, so that they can concentrate on those areas where their skills are most needed.

Join this webinar to hear more about automated embedding, hear evidence about Laboratories that have already made this change, reducing unnecessary repetitive manual work and using their time to the maximum benefit of the patient.

The average medium sized Laboratory embedding 500 blocks per day, can save in excess of 200 staff days per year by automating and standardising their embedding. Labs have used this staff time made free to decrease turnaround time to result, up skill-staff to perform other tasks, and to future proof their Labs for growth and increasing demands.

Click here to register


David Byrne

Marketing Manager UK/Ire.

Sakura Finetek

John Robinson

Business Manager Ireland

Sakura Finetek

Click here to register

Imagine a world where you could concentrate on what matters most, where manual repetitive processes are reduced, where results are standardised where you can provide the best possible service for the patient in the shortest time?

What will that future look like?  join Sakura to see a glimpse into that future with the new Tissue-Tek SmartConnect® automated transfer system.

Join us and step into your future.

Sakura Finetek Europe launches Tissue-Tek SmartConnect®, a new chapter in automation and the next step for laboratories in achieving future-proof pathology.

The Tissue-Tek SmartConnect solution enables a fully automated continuous flow by connecting processing and embedding in the histology lab. An automated transfer system that creates a continuous flow between the SMART solutions Tissue-Tek Xpress® x120 Rapid Tissue Processor and Tissue-Tek AutoTEC® a120 Automated Embedding System.

This new innovative SMART solution enables a laboratory to optimise their workflow and work more efficiently, eliminating repetitive and unnecessary manual work.

Laboratory technicians can focus more on what matters most: taking care of the best possible patient journey.

When it comes to diagnosing cancer, we can’t afford to wait for what happens next.

A helping hand in your laboratory

With an increasing rise in the number of cancer cases, we see laboratories working as hard as they can to deal with cases in the limited time they have.  That’s why we believe they can use all the help they can get so they can work on what truly matters.

Meet SARA – The Smart Autonomous Robotic Assistant

Click here to register


David Byrne

Marketing Manager UK/Ire.

Sakura Finetek

John Robinson

Business Manager Ireland

Sakura Finetek

On-Demand Content

On Demand Content will follow.